Stay informed, stay ahead.
Novartis has announced strong results for its drug Fabhalta (iptacopan). The treatment slowed the progression of IgA nephropathy, a rare and serious kidney disease, in a major clinical trial. In the Phase III study, patients taking Fabhalta had a much slower loss of kidney function compared to those on placebo. The drug improved the eGFR…
Danes’ biotech powerhouse Novo Nordisk has agreed to pay up to $2.1 billion to license and acquire rights to Omeros’ experimental drug, zaltenibart, positioning itself for a bigger role in rare disease treatment. Under the deal, Novo will gain global development and marketing rights to zaltenibart, while Omeros receives $340 million upfront, plus additional milestone…
Novo Nordisk has quietly initiated job cuts at its Clayton, North Carolina facility—the company’s largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs—according to LinkedIn profiles and internal posts. These reductions target frontline roles from quality control to production technicians, underscoring how deep the restructuring is going under new CEO Mike Doustdar. The…
